Haleon plc (LON:HLN - Get Free Report) has earned an average rating of "Hold" from the six brokerages that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is GBX 393.67.
HLN has been the topic of several analyst reports. JPMorgan Chase & Co. cut their target price on Haleon from GBX 335 to GBX 315 and set an "underweight" rating on the stock in a research note on Thursday, June 25th. Deutsche Bank Aktiengesellschaft restated a "sell" rating and issued a GBX 325 target price on shares of Haleon in a research note on Wednesday, July 1st. Jefferies Financial Group decreased their price objective on shares of Haleon from GBX 450 to GBX 400 and set a "buy" rating for the company in a research note on Tuesday, May 5th. Berenberg Bank reissued a "buy" rating and issued a GBX 512 price objective on shares of Haleon in a report on Thursday, April 30th. Finally, Royal Bank Of Canada reiterated a "sector perform" rating and issued a GBX 370 target price on shares of Haleon in a research note on Thursday, April 30th.
Check Out Our Latest Stock Analysis on Haleon
Haleon Stock Performance
Shares of HLN stock opened at GBX 358.50 on Thursday. Haleon has a 52-week low of GBX 317.80 and a 52-week high of GBX 416.10. The company's 50 day moving average is GBX 341.49 and its 200 day moving average is GBX 363.30. The firm has a market cap of £31.58 billion, a price-to-earnings ratio of 19.38, a PEG ratio of 1.49 and a beta of 0.24. The company has a quick ratio of 0.93, a current ratio of 0.92 and a debt-to-equity ratio of 52.26.
About Haleon
(
Get Free Report)
Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.
Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
